136 related articles for article (PubMed ID: 7546988)
1. Neutralising antibodies after streptokinase treatment for myocardial infarction: a persisting puzzle.
McGrath K; Hogan C; Hunt D; O'Malley C; Green N; Dauer R; Dalli A
Br Heart J; 1995 Aug; 74(2):122-3. PubMed ID: 7546988
[TBL] [Abstract][Full Text] [Related]
2. Clinical usefulness of a functional test of neutralising streptokinase antibodies for the prediction of the thrombolytic effect of streptokinase in acute myocardial infarction.
Gill S; Kristensen SR; Haastrup B; Haghfelt T
Cardiology; 2003; 100(1):36-40. PubMed ID: 12975544
[TBL] [Abstract][Full Text] [Related]
3. Streptokinase antibodies inhibit reperfusion during thrombolytic therapy with streptokinase in acute myocardial infarction.
Juhlin P; Boström PA; Torp A; Bredberg A
J Intern Med; 1999 May; 245(5):483-8. PubMed ID: 10363749
[TBL] [Abstract][Full Text] [Related]
4. The effect of streptokinase neutralizing antibodies on fibrinolytic activity and reperfusion following streptokinase treatment in acute myocardial infarction.
Nilsson JB; Nilsson TK; Jansson JH; Boman K; Söderberg S; Näslund U
J Intern Med; 2002 Nov; 252(5):405-11. PubMed ID: 12528758
[TBL] [Abstract][Full Text] [Related]
5. [Anti-streptokinase antibodies].
Helft G; Lecompte T; Le Feuvre C; Metzger JP; Vacheron A; Samama MM
Arch Mal Coeur Vaiss; 1997 Jul; 90(7):975-80. PubMed ID: 9339259
[TBL] [Abstract][Full Text] [Related]
6. Can anti-streptokinase antibody predict myocardial infarction outcomes after streptokinase treatment?
Sadeghi M; Golabchi A; Haghani P; Gharipour M; Naderi GA; Sarrafzadegan N
J Pak Med Assoc; 2012 Mar; 62(3 Suppl 2):S31-4. PubMed ID: 22768454
[TBL] [Abstract][Full Text] [Related]
7. Streptokinase-induced hypotension has no detrimental effect on patients with thrombolytic treatment for acute myocardial infarction. A substudy of the Romanian Study for Accelerated Streptokinase in Acute Myocardial Infarction (ASK-ROMANIA).
Tatu-Chiţoiu G; Teodorescu C; Dan M; Guran M; Căpraru P; Istrăţescu O; Tatu-Chiţoiu A; Bumbu A; Chioncel V; Arvanitopol S; Dorobanţu M
Rom J Intern Med; 2004; 42(3):557-73. PubMed ID: 16366130
[TBL] [Abstract][Full Text] [Related]
8. Anti-streptokinase titers and response to streptokinase treatment in Pakistani patients.
Kazmi KA; Perwaiz Iqbal M; Rahbar A; Mehboobali N
Int J Cardiol; 2002 Mar; 82(3):247-51. PubMed ID: 11911912
[TBL] [Abstract][Full Text] [Related]
9. Effect of pretreatment antistreptokinase antibody and streptococcal infection on the efficacy and dosage of streptokinase in acute myocardial infarction.
Abuosa AM; Akhras F; Sorour K; El-Said G; El-Tobgy S; Kinsara AJ
Saudi Med J; 2005 Jun; 26(6):934-6. PubMed ID: 15983677
[TBL] [Abstract][Full Text] [Related]
10. Thrombolysis with recombinant streptokinase in Cuba.
Lopez-Saura PA
BMJ; 2003 Feb; 326(7386):448. PubMed ID: 12595394
[No Abstract] [Full Text] [Related]
11. Platelet reactivity and streptokinase resistance following antecedent streptokinase therapy for myocardial infarction.
Gorog DA; Ahmed N; Davies GJ
Cardiology; 1999; 91(1):56-9. PubMed ID: 10393399
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin response to intravenous streptokinase in acute myocardial infarction.
Lynch M; Littler WA; Pentecost BL; Stockley RA
Br Heart J; 1991 Aug; 66(2):139-42. PubMed ID: 1883664
[TBL] [Abstract][Full Text] [Related]
13. Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase.
Berrocal DH; Cohen MG; Spinetta AD; Ben MG; Rojas Matas CA; Gabay JM; Magni JM; Nogareda G; Oberti P; Von Schulz C; Doval H; Bazzino OO; Cagide A; Oliveri R; Grinfeld LR
Am Heart J; 2003 Dec; 146(6):E22. PubMed ID: 14661011
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial of China-made recombinant streptokinase in acute myocardial infarction. Collaborative Study Group on Thrombolysis with China-made recombinant streptokinase.
Chin Med J (Engl); 1997 Jan; 110(1):50-2. PubMed ID: 9594322
[TBL] [Abstract][Full Text] [Related]
15. The distribution of antibodies to streptokinase.
Lynch M; Pentecost BL; Littler WA; Stockley RA
Postgrad Med J; 1996 May; 72(847):290-2. PubMed ID: 8761502
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG.
Fears R; Ferres H; Glasgow E; Standring R; Hogg KJ; Gemmill JD; Burns JM; Rae AP; Dunn FG; Hillis WS
Br Heart J; 1992 Aug; 68(2):167-70. PubMed ID: 1389731
[TBL] [Abstract][Full Text] [Related]
17. Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for acute myocardial infarction.
Patel S; Jalihal S; Dutka DP; Morris GK
Br Heart J; 1993 Aug; 70(2):119-21. PubMed ID: 8038019
[TBL] [Abstract][Full Text] [Related]
18. Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?
Brügemann J; de Graeff PA; van der Meer J; Lie KI
Drugs Aging; 1995 Aug; 7(2):110-6. PubMed ID: 7579782
[TBL] [Abstract][Full Text] [Related]
19. Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective.
Heyland DK; Gafni A; Levine MA
J Clin Epidemiol; 2000 Sep; 53(9):888-94. PubMed ID: 11004415
[TBL] [Abstract][Full Text] [Related]
20. Antistreptokinase titres after intravenous streptokinase.
Jalihal S; Morris GK
Lancet; 1990 Jan; 335(8683):184-5. PubMed ID: 1967665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
